INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT...Manufacturing and Supply Agreement • April 5th, 2017 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations • New York
WHEREAS, the Parties have entered into a license agreement for the PRODUCT (as defined below) dated February 13, 2017 (the “License Agreement”) under which ENDOCEUTICS granted the distribution rights of the PRODUCT to AMAG in the Territory (as defined below).
INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT...License Agreement • April 5th, 2017 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (the “Agreement”) is entered into as of February 13, 2017 (the “Execution Date”), by and between ENDOCEUTICS, INC., a Canadian corporation (“Endoceutics”), having an address of 2989, rue de la Promenade, Quebec City, Quebec, G1W 2J5, Canada, and AMAG PHARMACEUTICALS, INC., a corporation organized under the laws of Delaware (“AMAG”), having an address of 1100 Winter Street, Waltham, MA 02451. Endoceutics and AMAG may be referred to herein individually as a “Party” or collectively as the “Parties”.
